Prognostic Factors in Patients with Gemcitabine-Refractory Pancreatic Cancer-Reference-Cited by-同舟云学术

Prognostic Factors in Patients with Gemcitabine-Refractory Pancreatic Cancer

Published:2007-02-01 Issue:2 Volume:37 Page:114-120
ISSN:1465-3621
Container-title:Japanese Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Nakachi Kohei,Furuse Junji,Ishii Hiroshi,Suzuki Ei-ichiro,Yoshino Masahiro

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://academic.oup.com/jjco/article-pdf/37/2/114/5081357/hyl144.pdf

Reference36 articles.

1. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;Burris;J Clin Oncol,1997

2. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG];Moore;Proc Am Soc Clin Oncol,2005

3. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial;Xiong;J Clin Oncol,2004

4. Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy;Ueno;Oncology,2000

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. C-Reactive Protein Signaling Pathways in Tumor Progression;Biomolecules & Therapeutics;2023-08-11

2. Treatment outcomes of erlotinib plus gemcitabine as late-line chemotherapy in unresectable pancreatic cancer;Japanese Journal of Clinical Oncology;2021-06-14

3. Efficacy of S‐1 in second‐line chemotherapy after nab‐paclitaxel plus gemcitabine for patients with advanced pancreatic cancer;CANCER REPORTS;2020-04

4. External validation of the Besançon nomogram in Asian patients with advanced pancreatic cancer receiving second-line chemotherapy: A multi-institute experience in Taiwan;Pancreatology;2020-01

5. Development and validation of a prognostic nomogram to predict survival in patients with advanced pancreatic cancer receiving second‐line palliative chemotherapy;Journal of Gastroenterology and Hepatology;2019-11-28